

There is a test that can help guide your next step:

Biomarker testing for PTEN deficiency in people with metastatic prostate cancer



Actor portrayals.

MAN
WITH A
PLAN

TRUQAP + abiraterone with prednisone is
for certain people with metastatic* prostate
cancer that is PTEN-deficient

*Metastatic=cancer that has spread to other parts of the body.
PTEN=phosphatase and tensin homolog.

IMPORTANT PRODUCT INFORMATION

TRUQAP is a prescription oral medicine used in combination with the medicines abiraterone and prednisone to treat adults who have PTEN-deficient prostate cancer that has spread to other parts of the body (metastatic). Do not take TRUQAP if you have had a severe allergic reaction to TRUQAP or are allergic to any of its ingredients. Males with female partners who are able to become pregnant should use effective birth control during your treatment with TRUQAP and for 4 months after the last dose. If your female partner becomes pregnant, tell your healthcare provider right away. TRUQAP may cause severe side effects, including high blood sugar levels (hyperglycemia); diarrhea; or skin reactions. Untreated severe hyperglycemia can lead to a condition called diabetic ketoacidosis that requires treatment in a hospital and can lead to death. The most common side effects include skin reactions, diarrhea, tiredness, and changes in certain blood tests.

**Please see full Prescribing
Information, including Patient
Information for TRUQAP.**

 **Truqap®**
capiivasertib
160 mg • 200 mg tablets

What are biomarkers and why do they matter in metastatic* prostate cancer (mPC)?

You or your loved one may have heard the doctor talk about **“biomarkers.”** Biomarkers are signs in your body that doctors can find to learn more about your health.

In cancer treatment, they can give doctors clues about how the cancer may behave.



One important biomarker in mPC is PTEN deficiency.

What is PTEN deficiency?

PTEN deficiency refers to a lack of PTEN, a protein that blocks cancer signals. **When PTEN deficiency is detected, there is an additional path for the tissue to grow despite hormone therapy, which may lead to aggressive tumor growth.** Your doctor or healthcare team may refer to PTEN deficiency as PTEN loss.



Approximately 1 in 4 people with metastatic prostate cancer that is responding to hormone therapy have tumors that are PTEN-deficient.

*Metastatic=cancer that has spread to other parts of the body.



Actor portrayals.

How is PTEN deficiency tested?

To check for PTEN deficiency, doctors often use a test called IHC on a sample of the tumor.

What to expect with IHC testing:

- A small tissue sample is taken through a biopsy (the doctor may use tissue from a previous biopsy)
- The doctor may review the results with you and explain what they may mean

Can PTEN deficiency change your treatment plan?

It may. People with metastatic prostate cancer normally receive hormone therapy to control tumor growth that's caused by testosterone (a hormone). But when tumors are PTEN-deficient, there is an additional path for the tissue to grow despite hormone therapy. Because of this, combining hormone therapy with another treatment that specifically targets PTEN deficiency may be right for certain people with metastatic prostate cancer that is PTEN-deficient.

Because PTEN deficiency may lead to aggressive tumor growth, timely testing is important. If biomarker testing hasn't been discussed yet, consider asking:



**“Have we tested for PTEN deficiency?
If not, would testing help guide next steps?”**

Knowing your or your loved one's PTEN status can help the doctor determine if a treatment that specifically addresses PTEN deficiency may be appropriate.

Ask about the first and only targeted combination therapy of its kind that is available for certain people with metastatic prostate cancer that is PTEN-deficient.

Please see full Prescribing Information, including Patient Information for TRUQAP.

Taking what comes next one step at a time

The following steps may help you or your loved one start important conversations and ensure you have the information you need.



Talking to the doctor about biomarker testing

Ask your doctor about biomarker testing for PTEN deficiency.



Learning about TRUQAP as a treatment option

Find out how TRUQAP works, and ask if TRUQAP + abiraterone with prednisone may be right for you or your loved one.



Downloading the doctor discussion guide

Scan the QR code to access the doctor discussion guide.

[Download the Doctor Discussion Guide](#)



Please see full [Prescribing Information](#), including [Patient Information](#) for TRUQAP.

Is PTEN testing covered?

Many biomarker tests, including immunohistochemistry, or an IHC test, which test for PTEN deficiency, are often covered by insurance.

If you'd like a test for PTEN deficiency and/or your doctor has prescribed TRUQAP, you may have questions. The AstraZeneca Access 360[™] program can help.

We can answer your questions about:



Insurance coverage



Out-of-pocket costs



Patient assistance programs



To learn more about the program, please call
1-844-ASK-A360 (1-844-275-2360)
Monday through Friday, 8 AM – 6 PM ET
or visit www.MyAccess360.com

Explore the Savings

Patients may pay

\$0
co-pay offer

You may be able to pay as little as \$0 per month with the TRUQAP Patient Savings Program*

*Subject to eligibility. Restrictions apply.

MAN WITH A PLAN AND TRUQAP

TRUQAP + abiraterone with prednisone
is for certain people with metastatic*
prostate cancer that is PTEN-deficient



Actor portrayal.

Biomarker testing may help your doctor to:

- Better understand your diagnosis
- Determine whether a targeted therapy may be an option
- Plan next steps

Visit [TRUQAP.com](https://www.truqap.com)
to learn more



*Metastatic=cancer that has spread to other parts of the body.

IMPORTANT PRODUCT INFORMATION

TRUQAP is a prescription oral medicine used in combination with the medicines abiraterone and prednisone to treat adults who have PTEN-deficient prostate cancer that has spread to other parts of the body (metastatic). Do not take TRUQAP if you have had a severe allergic reaction to TRUQAP or are allergic to any of its ingredients. Males with female partners who are able to become pregnant should use effective birth control during your treatment with TRUQAP and for 4 months after the last dose. If your female partner becomes pregnant, tell your healthcare provider right away. TRUQAP may cause severe side effects, including high blood sugar levels (hyperglycemia); diarrhea; or skin reactions. Untreated severe hyperglycemia can lead to a condition called diabetic ketoacidosis that requires treatment in a hospital and can lead to death. The most common side effects include skin reactions, diarrhea, tiredness, and changes in certain blood tests.

**Please see full Prescribing Information,
including Patient Information for TRUQAP.**



TRUQAP is a registered trademark and
AstraZeneca Access 360 is a trademark of the
AstraZeneca group of companies.
©2026 AstraZeneca. All rights reserved.
US-108328 Last Updated 6/26

 **Truqap®**
capivasertib
160 mg • 200 mg tablets